Clinical Trials Logo

Clinical Trial Summary

Peripartum cardiomyopathy (PPCM) is a global disease with significant morbidity and mortality, and Nigeria probably has the highest burden of the disease in the world. Unfortunately, much about the disease including its aetiology, epidemiology and treatment is not yet well described. This will be a prospective, national, multicenter cohort study, conducted in centres in Nigeria. It is expected that approximately 500 patients with PPCM and 500 apparently healthy pregnant women will be recruited over a 6-month period with follow-up at 3-monthly intervals for 18 months.


Clinical Trial Description

Peripartum cardiomyopathy (PPCM) is a global disease with significant morbidity and mortality, and Nigeria probably has the highest burden of the disease in the world. Unfortunately, much about the disease including its aetiology, epidemiology and treatment is not yet well described. This will be a prospective, national, multicenter cohort study, conducted in centres in Nigeria. It is expected that approximately 500 patients with PPCM and 500 apparently healthy pregnant women will be recruited over a 6-month period with follow-up at 3-monthly intervals for 18 months. The objectives of the study are: i. To describe the burden and demographic, social and clinical characteristics of PPCM in Nigeria. ii. To describe the ventricular remodelling and outcomes (rehospitalisation rate, cardio-embolic events and survival) of PPCM in Nigeria. Sub-study: iii. To study the relationship between selenium deficiency, oxidative stress and PPCM in Nigeria. iv. To describe the prevalence of selenium deficiency and its relationship with cardiac function in apparently healthy pregnant women in Nigeria. v. To study the impact of sodium selenite supplementation on cardiac function among selenium deficient PPCM patients who have not recovered left ventricular function at 6 months after the diagnosis. This will be the largest systematic evaluation of PPCM in Nigeria, and it is hoped that the information will assist in developing locally applicable treatment guidelines, policies and interventions for this seemingly deadly disease. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03081949
Study type Interventional
Source Aminu Kano Teaching Hospital
Contact
Status Completed
Phase Phase 4
Start date June 12, 2017
Completion date December 31, 2019

See also
  Status Clinical Trial Phase
Completed NCT04144660 - "Treatment Use of ECMO In Pregnancy or Peripartum Patient."
Withdrawn NCT04143997 - Diastolic Dysfunction PPCM in Patients With Documented Left Ventricular Systolic Function Recovery
Completed NCT00998556 - Effect of Bromocriptine on Left Ventricular Function in Women With Peripartum Cardiomyopathy Phase 2
Recruiting NCT03364140 - A Registry of Peripartum Cardiomyopathy in Turkey N/A
Completed NCT04049136 - NT-proBNP Levels and Obesity in Pregnancy
Recruiting NCT04234659 - PPCM Observational Study (Peripartum Cardiomyopathy)
Withdrawn NCT02590601 - Bromocriptine in the Treatment of Peripartum Cardiomyopathy Phase 3
Completed NCT03907267 - Taurine in Peripartum Cardiomyopathy Phase 2/Phase 3
Recruiting NCT05878041 - Creation of a Multicenter National Registry for Peripartum Cardiomyopathy.
Recruiting NCT04927715 - Irisin Expression and Gene Polymorphism With Peripartum Cardiomyopathy.